All articles by
J&J to bolster dermatology portfolio with $850m acquisition of Proteologix
Johnson & Johnson (J&J) has agreed to acquire biotechnology company Proteologix for $850m in an all-cash deal aimed at advancing…
BMS’ Breyanzi gets FDA accelerated approval for follicular lymphoma
Bristol Myers Squibb (BMS) has received accelerated approval from the US Food and Drug Administration (FDA) for Breyanzi (lisocabtagene maraleucel;…
SN Bioscience’s SNB-101 secures FDA fast track status for SCLC
SN Bioscience has secured Fast Track Designation from the US Food and Drug Administration (FDA) for small cell lung cancer…
EC approves indication extension of Sobi’s Aspaveli for PNH in adults
Aspaveli is a targeted C3 therapy designed to regulate the overactivation of the complement cascade, a part of the body`s immune system.
Regeneron’s DB-OTO improves hearing in two children with genetic deafness
Regeneron Pharmaceuticals said that its investigational gene therapy DB-OTO has improved hearing in two young children with profound genetic deafness…
Health Canada approves TerSera’s Zoladex LA for ER+ breast cancer
Health Canada has approved TerSera’s supplemental new drug submission (sNDA) to use Zoladex LA 10.8mg in ER+ early breast cancer patients with a high risk of women in pre- and perimenopausal phase with recurrence or advanced breast cancer
Biotheryx announces US FDA clearance of IND application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4/6
Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets…
FDA clears Azurity’s Myhibbin as oral suspension for organ transplant recipients
Azurity Pharmaceuticals said that the US Food and Drug Administration (FDA) has approved Myhibbin as a ready-to-use mycophenolate mofetil oral…
AstraZeneca completes equity investment agreement with Cellectis
AstraZeneca today announced the successful completion of an equity investment with Cellectis, a clinical-stage biotechnology company. The equity investment and…
Bayer Pharmaceuticals takes full ownership of Bayer Zydus Pharma
Bayer Pharmaceuticals has taken full ownership of Bayer Zydus Pharma (BZPPL) by acquiring the remaining 25% from its joint venture…